A discovery about the mechanisms that enable the immune system to sustain long-term protection could revolutionize treatment for chronic disease and cancer.

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.

According to research, PSAT1, PSRC1, COLEC12, HP, and PLLP may play a role in small cell lung cancer metabolism, immune ...

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.

Media Release Marking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line ...

Among patients with stage IA non-small cell lung cancer, long-term survival was better with lobectomy or segmentectomy vs. wedge resection, according to results presented at the Society of Thoracic ...